Ogasawara K - Search Results

1

Phase 1 study of galunisertib, a TGF-beta receptor I kinase inhibitor, in Japanese patients with advanced solid tumors.

Fujiwara Y, Nokihara H, Yamada Y, Yamamoto N, Sunami K, Utsumi H, Asou H, TakahashI O, Ogasawara K, Gueorguieva I, Tamura T. Fujiwara Y, et al. Among authors: ogasawara k. Cancer Chemother Pharmacol. 2015 Dec;76(6):1143-52. doi: 10.1007/s00280-015-2895-4. Epub 2015 Nov 3. Cancer Chemother Pharmacol. 2015. PMID: 26526984 Clinical Trial.

2

Phase 1 study of abemaciclib, an inhibitor of CDK 4 and 6, as a single agent for Japanese patients with advanced cancer.

Fujiwara Y, Tamura K, Kondo S, Tanabe Y, Iwasa S, Shimomura A, Kitano S, Ogasawara K, Turner PK, Mori J, Asou H, Chan EM, Yamamoto N. Fujiwara Y, et al. Among authors: ogasawara k. Cancer Chemother Pharmacol. 2016 Aug;78(2):281-8. doi: 10.1007/s00280-016-3085-8. Epub 2016 Jun 16. Cancer Chemother Pharmacol. 2016. PMID: 27312735 Clinical Trial.

3

Phase 1b study of galunisertib in combination with gemcitabine in Japanese patients with metastatic or locally advanced pancreatic cancer.

Ikeda M, Takahashi H, Kondo S, Lahn MMF, Ogasawara K, Benhadji KA, Fujii H, Ueno H. Ikeda M, et al. Among authors: ogasawara k. Cancer Chemother Pharmacol. 2017 Jun;79(6):1169-1177. doi: 10.1007/s00280-017-3313-x. Epub 2017 Apr 27. Cancer Chemother Pharmacol. 2017. PMID: 28451833 Clinical Trial.

4

Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia.

Ogasawara K, Zhou S, Krishna G, Palmisano M, Li Y. Ogasawara K, et al. Cancer Chemother Pharmacol. 2019 Oct;84(4):891-898. doi: 10.1007/s00280-019-03929-9. Epub 2019 Aug 23. Cancer Chemother Pharmacol. 2019. PMID: 31444617 Free PMC article. Clinical Trial.

5

Effects of repeated oral doses of ketoconazole on a sequential ascending single oral dose of fedratinib in healthy subjects.

Ogasawara K, Xu C, Kanamaluru V, Palmisano M, Krishna G. Ogasawara K, et al. Cancer Chemother Pharmacol. 2020 May;85(5):899-906. doi: 10.1007/s00280-020-04067-3. Epub 2020 Apr 4. Cancer Chemother Pharmacol. 2020. PMID: 32248324

6

A phase I study of the effect of repeated oral doses of pantoprazole on the pharmacokinetics of a single dose of fedratinib in healthy male subjects.

Ogasawara K, Vince B, Xu C, Zhang M, Palmisano M, Krishna G. Ogasawara K, et al. Cancer Chemother Pharmacol. 2020 May;85(5):995-1001. doi: 10.1007/s00280-020-04074-4. Epub 2020 Apr 22. Cancer Chemother Pharmacol. 2020. PMID: 32318809 Clinical Trial.

7

Pharmacokinetics and tolerability of fedratinib, an oral, selective Janus kinase 2 inhibitor, in subjects with renal or hepatic impairment.

Ogasawara K, Smith WB, Xu C, Yin J, Palmisano M, Krishna G. Ogasawara K, et al. Cancer Chemother Pharmacol. 2020 Jun;85(6):1109-1117. doi: 10.1007/s00280-020-04084-2. Epub 2020 May 24. Cancer Chemother Pharmacol. 2020. PMID: 32449142 Clinical Trial.

8

Assessment of effects of repeated oral doses of fedratinib on inhibition of cytochrome P450 activities in patients with solid tumors using a cocktail approach.

Ogasawara K, LoRusso PM, Olszanski AJ, Rixe O, Xu C, Yin J, Palmisano M, Krishna G. Ogasawara K, et al. Cancer Chemother Pharmacol. 2020 Jul;86(1):87-95. doi: 10.1007/s00280-020-04102-3. Epub 2020 Jun 14. Cancer Chemother Pharmacol. 2020. PMID: 32537715 Clinical Trial.

9

Effect of fluconazole on the pharmacokinetics of a single dose of fedratinib in healthy adults.

Chen Y, Ogasawara K, Wood-Horrall R, Thomas M, Thomas M, He B, Liu L, Xue Y, Surapaneni S, Carayannopoulos LN, Zhou S, Palmisano M, Krishna G. Chen Y, et al. Among authors: ogasawara k. Cancer Chemother Pharmacol. 2022 Oct;90(4):325-334. doi: 10.1007/s00280-022-04464-w. Epub 2022 Aug 24. Cancer Chemother Pharmacol. 2022. PMID: 36001108 Free PMC article.

10

Excretion balance and pharmacokinetics following a single oral dose of [¹⁴C]-fedratinib in healthy subjects.

Ogasawara K, Xu C, Kanamaluru V, Siebers N, Surapaneni S, Ridoux L, Palmisano M, Krishna G. Ogasawara K, et al. Cancer Chemother Pharmacol. 2020 Aug;86(2):307-314. doi: 10.1007/s00280-020-04121-0. Epub 2020 Aug 3. Cancer Chemother Pharmacol. 2020. PMID: 32748109

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,465 results

Search Page

Filters